为了制定更好的治疗方案和结果，前列腺癌临床试验需要更多多样性。
研究从2021年显示，前列腺癌的临床试验中有96％的参与者是非西班牙裔白人。然而，黑人中前列腺癌的发病率比白人男性高2.2倍，死亡率较高的1.7倍。
Black men also present with more advanced disease and higher prostate-specific antigen (PSA) levels, which indicate the presence of prostate cancer. This means Black men, among other historically marginalized groups, are inadequately represented in prostate cancer clinical trials, despite having increased risks.
虽然没有明确的原因,这些更高的怒mbers, several factors can affect cancer risk, including culture, religion, and socioeconomic status.
Racial disparities in prostate cancer clinical trials can contribute to disparate outcomes for men diagnosed with the disease.
以下是您需要了解的一切关于前列腺癌统计数据，今天临床试验站立，以及如何越来越多的多样性可以节省更多的生命。
在2022年，
根据本组织的说法，8名男性约有1人将在生活中的某些时候诊断前列腺癌，并且疾病更有可能在老年人和非西班牙裔黑人身上开发。这是因为50岁以后有前列腺癌的可能性迅速上升。由于上述原因，非西班牙裔黑人男性可能处于更高的风险。
在美国，前列腺癌是肺癌背后癌症死亡的第二个主要原因。据估计，41名男性中有1人将死于前列腺癌。
然而
That’s why diverse prostate cancer clinical trials are so important and can help improve outcomes in years to come.
A clinical trial is a research study that uses experiments or observations in human participants to evaluate effects on health outcomes. This can include studies on new therapies, vaccines, surgeries, or diagnostic tests.
临床试验有助于确定治疗或药物是否有效，如何与其他治疗进行比较，以及它们是否具有任何副作用。这有助于研究人员和医学专家决定有多有效和安全的治疗方法，并确定如何提高生活质量。
Diverse clinical trials matter. They help medical professionals and researchers better define the impact of therapy, quality of life, and how biomarkers impact different patient populations.
Since the majority of participants in clinical trials for prostate cancer are non-Hispanic white men, there is little opportunity to study direct effects on People of Color.
In addition to the risk Black men face, Puerto Rican men also see a 60 percent increased incidence of prostate cancer and 44 percent higher rate of death when compared with non-Hispanic white men, reports a2012年研究。
根据2021年研究。
There’s an even greater disparity for Hispanic or Latino men, who make up less than 2 percent of prostate cancer clinical trial participants.
从不同的临床试验中获得的结果有助于医疗专业人员和研究人员了解种族和种族如何影响前列腺癌风险和结果。
These results enable factors like cultural tradition, common history, religion, and socioeconomic factors and their influence on the development of prostate cancer to be studied.
In addition, diverse clinical trials can help researchers identify issues related to preventive screenings access — or lack thereof — as well as a person’s ability to seek treatment.
研究这些因素还可以帮助确定饮食，身体活动和遗传等程度影响培养前列腺癌的风险。文化因素可以在健康行为中发挥关键作用，对疾病的态度，以及在其他元素中对现代医学的信仰。
多元化前列腺癌临床试验对于对所有人的正确治疗是必不可少的。非凡的临床试验可能导致遭受消极结果的非争辩人口，例如获得错误的药物或接受对其特定需求的治疗。
目标是用于纳入前列腺癌临床试验的颜色，一般的医疗保健临床试验。这比完成这么容易。
男人可以通过访问来发现或注册临床试验ClinicalTrials.gov.。此可搜索的注册表和结果数据库包括联邦和私人支持在美国和全球范围内进行的临床试验。
A lack of resources, like limitations of translator services for men who speak a language other than English, can contribute to decreased recruitment of participants from marginalized groups. Systemic and institutional barriers can also reduce access to enrollment, as can lack of healthcare insurance.
While some of these factors ultimately depend on larger systemic changes, there are some steps people can take to help diversify prostate cancer clinical trials. These include:
- 优先考虑订婚和外展
- 注册临床试验
- joining a registry, such as the铁人登记处
Collecting and researching this information can help medical experts better understand what causes prostate cancer, how to stop or slow its progression, and how to provide care that allows men of all racial groups to experience the best quality of life.
As we continue to address prostate cancer risks and death rates, diverse clinical trials can go a long way in facilitating better outcomes for all men, regardless of racial or ethnic background.